Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. decreased its stake in Immatics (NASDAQ:IMTX) by 4.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 286,769 shares of the company’s stock after selling 12,297 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.24% of Immatics worth $2,039,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of IMTX. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Immatics by 24.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company’s stock worth $163,000 after buying an additional 4,477 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Immatics in the fourth quarter worth approximately $211,000. State Street Corp increased its position in shares of Immatics by 11.2% during the third quarter. State Street Corp now owns 225,202 shares of the company’s stock worth $2,570,000 after purchasing an additional 22,710 shares in the last quarter. Platinum Investment Management Ltd. raised its stake in Immatics by 53.1% in the 4th quarter. Platinum Investment Management Ltd. now owns 311,722 shares of the company’s stock valued at $2,216,000 after purchasing an additional 108,108 shares during the last quarter. Finally, abrdn plc lifted its holdings in Immatics by 49.2% in the 4th quarter. abrdn plc now owns 347,379 shares of the company’s stock valued at $2,470,000 after purchasing an additional 114,479 shares in the last quarter. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Stock Performance

NASDAQ:IMTX opened at $4.67 on Friday. Immatics has a one year low of $3.30 and a one year high of $13.77. The stock has a market cap of $567.64 million, a PE ratio of -7.08 and a beta of 0.85. The stock has a 50 day moving average price of $4.43 and a 200 day moving average price of $6.41.

Immatics (NASDAQ:IMTX) last issued its earnings results on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.51. The business had revenue of $15.67 million during the quarter, compared to the consensus estimate of $16.16 million. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. As a group, analysts predict that Immatics will post -0.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immatics in a report on Tuesday, April 1st. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $16.67.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.